Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations

作     者：Ozkan Kanat Hulya Ertas Burcu Caner 

作者机构：Department of Medical OncologyAcıbadem Bursa HospitalBursa 16059Turkey Department of Medical OncologyBursa City HospitalBursa 16059Turkey Department of Medical OncoloyBalıkesir Ataturk City HospitalBursa 16059Turkey 

出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文版）（电子版）)

年 卷 期：2020年第12卷第10期

页      面：1080-1090页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：BRAF mutation V600 mutations Metastatic colorectal cancer Targeted therapies 

摘      要：The treatment of metastatic colorectal cancer(mCRC)harboring BRAF V600 mutations is *** tumors are often refractory to standard ***,the patients may exhibit rapid clinical deterioration,depriving them of the chance to receive salvage *** newly diagnosed patients with good performance status,the administration of an intensive chemotherapy regimen like FOLFOXIRI(5-fluorouracil,leucovorin,oxaliplatin,and irinotecan)along with the antiangiogenic agent bevacizumab can modify this aggressive behavior of the disease and improve patient clinical *** recently published results of the BEACON(Binimetinib,Encorafenib,and Cetuximab Combined to Treat BRAF-Mutant Colorectal Cancer)study demonstrated that a combination therapy consisting of BRAF,epidermal growth factor receptor,and mitogen-activated protein kinase kinase inhibitors could be a useful second-or third-line *** review summarizes the current treatment strategies for BRAF-mutant mCRC.